Answers are grounded in this paper and cite their sources.
Findings reveal targeting PKCβ improves apoptosis in chronic lymphocytic leukemia, suggesting a strategy to overcome BTK inhibitor resistance.
Summary: Resistance of chronic lymphocytic leukemia to BTK inhibitors poses a major clinical challenge; however, there is potential to overcome this obstacle by targeting the downstream protein kinase PKCβ using the novel inhibitor MS-553. By inhibiting PKCβ, MS-553 blocks B-cell receptor signaling and WNT/β-catenin and NF-κB functions, thereby inducing apoptosis in BTK inhibitor–resistant cells. See related article by Gordon et al., p. XX .
No takes yet. Share an insight, caveat, or question.
Jebaraj et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: